Levocetirizine
- Generic Name
- Levocetirizine
- Brand Names
- Xyzal
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O3
- CAS Number
- 130018-77-8
- Unique Ingredient Identifier
- 6U5EA9RT2O
- Background
Levocetirizine is a selective histamine H antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H receptor than cetirizine.
Levocetirizine was granted FDA approval in 1995.
- Indication
Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It is also used over the counter for a variety of mild allergy symptoms.
- Associated Conditions
- Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR
- Conditions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 459
- Registration Number
- NCT00521040
Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Institut für Atemwegsforschung GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT00439712
- Locations
- 🇩🇪
Institut für Atemwegsforschung GmbH, Düsseldorf, Nordrhein-Westfalen, Germany
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 522
- Registration Number
- NCT00421109
- Locations
- 🇧🇪
Centre nº 204, Gent, Belgium
🇦🇷Centre nº 107, Buenos Aires, Argentina
🇵🇱Centre nº 507, Krakow, Poland
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 466
- Registration Number
- NCT00375713
The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)
- Conditions
- Interventions
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 36
- Registration Number
- NCT00359138
Levocetirizine 5 mg: Reduction of Symptoms, Airway Resistance and Sleep Impairment in Persistent Allergic Rhinitis
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Institut für Atemwegsforschung GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT00355771
- Locations
- 🇨🇳
Department of ORL, West China Hospital, Sichuan Hospital, Chengdu, Sichuan, China
Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen
- Conditions
- First Posted Date
- 2006-04-18
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 403
- Registration Number
- NCT00315523
Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects
- Conditions
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- UCB S.A. - Pharma Sector
- Target Recruit Count
- 418
- Registration Number
- NCT00295022
CUTE (Chronic Urticaria Treatment Evaluation)
- Conditions
- Interventions
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 886
- Registration Number
- NCT00264303
LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 729
- Registration Number
- NCT00160589
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.